The China Mail - Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

USD -
AED 3.672994
AFN 70.194145
ALL 87.342841
AMD 388.911102
ANG 1.80229
AOA 916.999716
ARS 1126.879559
AUD 1.560306
AWG 1.8
AZN 1.703903
BAM 1.737794
BBD 2.017593
BDT 121.409214
BGN 1.737794
BHD 0.376738
BIF 2972.677596
BMD 1
BND 1.297259
BOB 6.904794
BRL 5.648499
BSD 0.999245
BTN 85.280554
BWP 13.549247
BYN 3.27007
BYR 19600
BZD 2.007197
CAD 1.39395
CDF 2871.999876
CHF 0.832049
CLF 0.024361
CLP 934.834955
CNY 7.237296
CNH 7.24022
COP 4248.70052
CRC 507.174908
CUC 1
CUP 26.5
CVE 97.974144
CZK 22.179802
DJF 177.937714
DKK 6.632095
DOP 58.79426
DZD 133.028566
EGP 50.592208
ERN 15
ETB 134.071527
EUR 0.888602
FJD 2.2692
FKP 0.751681
GBP 0.751965
GEL 2.745032
GGP 0.751681
GHS 13.139633
GIP 0.751681
GMD 71.504306
GNF 8653.427518
GTQ 7.685815
GYD 209.667244
HKD 7.778675
HNL 25.959394
HRK 6.698096
HTG 130.498912
HUF 359.259542
IDR 16550.45
ILS 3.54625
IMP 0.751681
INR 85.408501
IQD 1308.987516
IRR 42099.99978
ISK 130.609797
JEP 0.751681
JMD 158.834244
JOD 0.709301
JPY 145.377499
KES 129.148341
KGS 87.450346
KHR 4000.177707
KMF 436.501385
KPW 900.000002
KRW 1396.160031
KWD 0.3067
KYD 0.832734
KZT 515.695944
LAK 21600.248789
LBP 89531.298592
LKR 298.556133
LRD 199.848949
LSL 18.174153
LTL 2.95274
LVL 0.60489
LYD 5.476032
MAD 9.244125
MDL 17.126483
MGA 4495.979386
MKD 54.671465
MMK 2099.733149
MNT 3573.792034
MOP 8.005864
MRU 39.809854
MUR 45.709753
MVR 15.406315
MWK 1732.640277
MXN 19.43815
MYR 4.297019
MZN 63.901599
NAD 18.174153
NGN 1607.109733
NIO 36.767515
NOK 10.37227
NPR 136.448532
NZD 1.692119
OMR 0.384771
PAB 0.999245
PEN 3.630192
PGK 4.147674
PHP 55.367026
PKR 281.409214
PLN 3.765161
PYG 7988.804478
QAR 3.646186
RON 4.549801
RSD 104.145009
RUB 83.34444
RWF 1436.403216
SAR 3.7509
SBD 8.343881
SCR 14.203029
SDG 600.499973
SEK 9.712185
SGD 1.298601
SHP 0.785843
SLE 22.750265
SLL 20969.483762
SOS 571.060465
SRD 36.702496
STD 20697.981008
SVC 8.743169
SYP 13001.854971
SZL 18.166067
THB 32.970971
TJS 10.342085
TMT 3.51
TND 3.007952
TOP 2.342101
TRY 38.771315
TTD 6.788396
TWD 30.261399
TZS 2695.455151
UAH 41.510951
UGX 3657.203785
UYU 41.769959
UZS 12870.407393
VES 92.71499
VND 25978.5
VUV 121.00339
WST 2.778525
XAF 582.839753
XAG 0.03055
XAU 0.0003
XCD 2.70255
XDR 0.724866
XOF 582.839753
XPF 105.966502
YER 244.450485
ZAR 18.19765
ZMK 9001.207781
ZMW 26.305034
ZWL 321.999592
  • CMSD

    0.0100

    22.34

    +0.04%

  • BCC

    -0.9600

    88.62

    -1.08%

  • BCE

    0.4800

    22.71

    +2.11%

  • SCS

    -0.0200

    10.46

    -0.19%

  • RIO

    0.8000

    59.98

    +1.33%

  • RYCEF

    0.0500

    10.55

    +0.47%

  • NGG

    0.5100

    70.69

    +0.72%

  • RBGPF

    65.2700

    65.27

    +100%

  • GSK

    -0.2500

    36.62

    -0.68%

  • JRI

    0.0300

    12.98

    +0.23%

  • CMSC

    -0.0500

    22.06

    -0.23%

  • BTI

    -1.6600

    41.64

    -3.99%

  • RELX

    0.3486

    53.85

    +0.65%

  • BP

    1.1800

    29.77

    +3.96%

  • VOD

    0.0500

    9.3

    +0.54%

  • AZN

    0.2700

    67.57

    +0.4%

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

Canalevia®-CA1, Jaguar's first-generation antisecretory drug for the treatment of chemotherapy-induced diarrhea in dogs, has received extension of conditional approval by FDA

Jaguar is attending the December 3-5 Pet Connect conference and is available for NP300 partnership discussions at the event

Text size:

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

Canalevia®-CA1, Jaguar's first-generation antisecretory drug for the treatment of chemotherapy-induced diarrhea in dogs, has received extension of conditional approval by FDA

Jaguar is attending the December 3-5 Pet Connect conference and is available for NP300 partnership discussions at the event

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced that it is seeking a partner to fund and execute the development and commercialization of NP300, the company's prescription drug candidate for the treatment of general, non-infectious diarrhea in dogs, in exchange for commercial rights to the product in the U.S.

NP300 is a novel antisecretory drug with a similar mechanism of action to Canalevia®-CA1 (crofelemer delayed-release tablets), the company's conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs. NP300 has demonstrated safety in dogs and is sustainably derived from the Croton lechleri tree, the same source as that for crofelemer.

"We look forward to evaluating NP300 for treatment of general, non-infectious diarrhea in dogs, and to identifying a partner organization to fund and execute development and commercialization of the product," said David Sesin, PhD, Jaguar's Chief Manufacturing Officer. "We've been pleased with the marketplace reception of crofelemer for treatment of CID in dogs, and believe there is clearly an unmet need for a product to treat general, non-infectious diarrhea in dogs as well. We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs. We are attending the Pet Connect conference, which takes place December 3-5, 2024 in Hollywood, California, with the goal of speaking with potential partners about NP300."

Diarrhea is one of the most common reasons for veterinary office visits for dogs and is the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drug to treat canine diarrhea. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (45.5%) of U.S. households owning a dog in 2024. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of control in urban settings where owners don't have easy access to outdoor facilities is a significant problem for families with dogs.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Important Safety Information About Canalevia-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that company personnel will attend the December 3-5, 2024 Pet Connect conference, and Jaguar's expectation that it may identify a partner organization to fund and execute development and commercialization of NP300. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Source: Jaguar Health, Inc.

Contact:

[email protected]
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

P.Deng--ThChM